{"article_title": "Amgen Sees Positive Results From Kyprolis Study", "article_keywords": ["worsening", "sees", "positive", "study", "results", "drug", "amgen", "twice", "patients", "treatment", "kyprolis", "multiple", "myeloma", "taking", "velcade"], "article_url": "http://www.wsj.com/articles/amgen-sees-positive-results-from-kyprolis-study-1425258868", "article_text": "Amgen Inc. took a step forward in its efforts to make its Kyprolis cancer therapy a standard treatment for many multiple myeloma patients, saying the drug performed better than older rival Velcade in a study.\n\nAmgen, of Thousand Oaks, Calif., said patients taking Kyprolis as part of their drug regimen in the 929-subject study lived 18.7 months without their multiple myeloma worsening, about twice as long as patients taking the...", "article_metadata": {"article.template": "snippet", "article.created": "2015-03-02T01:14:00.000Z", "article.section": "Business", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "Amgen took a step forward in its efforts to make its Kyprolis cancer therapy a standard treatment for many multiple myeloma patients, saying the drug performed better than older rival Velcade in a study.", "creator": "@jonathanrockoff", "image": {"src": "https://si.wsj.net/public/resources/images/BN-HE486_amgen0_G_20150301210356.jpg", "alt": "Amgen sees positive results from Kyprolis study", "identifier": "https://si.wsj.net/public/resources/images/BN-HE486_amgen0_D_20150301210356.jpg"}, "title": "Amgen Sees Positive Results From Kyprolis Study", "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB11751083927496774362504580492662245641900&headline=Amgen%20sees%20positive%20results%20from%20Kyprolis%20study&weburl=http://www.wsj.com/articles/SB11751083927496774362504580492662245641900"}}, "page.site.product": "WSJ", "keywords": "amgen cancer drug,amgen kyprolis,drug study,fda,food and drug administration,kyprolis,kyprolis study,multiple myeloma,myeloma,velcade,Amgen,AMGN,Sean Harper,corporate,industrial news,cancer,political,general news,health,medical conditions,biotechnology,pharmaceuticals,health care,life sciences,biopharmaceuticals,drugs,medication", "news_keywords": "amgen cancer drug,amgen kyprolis,drug study,fda,food and drug administration,kyprolis,kyprolis study,multiple myeloma,myeloma,velcade", "article.headline": "Amgen sees positive results from Kyprolis study", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/BN-HE486_amgen0_E_20150301210356.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/BN-HE486_amgen0_D_20150301210356.jpg"}}, "description": "Amgen took a step forward in its efforts to make its Kyprolis cancer therapy a standard treatment for many multiple myeloma patients, saying the drug performed better than older rival Velcade in a study.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB11751083927496774362504580492662245641900&headline=Amgen%20sees%20positive%20results%20from%20Kyprolis%20study&weburl=http://www.wsj.com/articles/SB11751083927496774362504580492662245641900", "user.type": "nonsubscriber", "article.page": "Business", "page.content.format": "responsive", "article.summary": "Amgen took a step forward in its efforts to make its Kyprolis cancer therapy a standard treatment for many multiple myeloma patients, saying the drug performed better than older rival Velcade in a study.", "page.site": "wsj", "testkeys": "A", "article.published": "2015-03-02T01:22:00.000Z", "dj.asn": "i-73ed", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"internal_link_count": 2, "image_count": 1, "word_count": 419, "publisher": "https://www.facebook.com/wsj"}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "Amgen took a step forward in its efforts to make its Kyprolis cancer therapy a standard treatment for many multiple myeloma patients, saying the drug performed better than older rival Velcade in a study.", "title": "Amgen Sees Positive Results From Kyprolis Study", "url": "http://www.wsj.com/articles/amgen-sees-positive-results-from-kyprolis-study-1425258868", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/BN-HE486_amgen0_G_20150301210356.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "Jonathan D. Rockoff", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Amgen Sees Positive Results From Kyprolis Study", "article.type": "Business", "article.id": "SB11751083927496774362504580492662245641900", "user.exp": "default", "article.updated": "2015-03-02T01:22:00.000Z"}, "_id": "\"57477af36914bd0286fcbc83\"", "article_summary": "Amgen, of Thousand Oaks, Calif., said patients taking Kyprolis as part of their drug regimen in the 929-subject study lived 18.7 months without their multiple myeloma worsening, about twice as long as patients taking the...\nAmgen Inc. took a step forward in its efforts to make its Kyprolis cancer therapy a standard treatment for many multiple myeloma patients, saying the drug performed better than older rival Velcade in a study."}